C12Y 301/06013
Iduronate-2-sulfatase
Official title: Iduronate-2-sulfatase (3.1.6.13)
C12Y301/06013 (Iduronate-2-sulfatase) appears on 77 US grants and 170 published applications in this corpus.
Search patents in C12Y- Granted patents
- 77
- Published applications
- 170
- Assignees
- 51
- Inventors
- 292
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 4 |
| 2012 | 1 | 3 |
| 2013 | 2 | 7 |
| 2014 | 1 | 7 |
| 2015 | 7 | 10 |
| 2016 | 6 | 11 |
| 2017 | 5 | 6 |
| 2018 | 4 | 16 |
| 2019 | 5 | 13 |
| 2020 | 7 | 17 |
| 2021 | 9 | 16 |
| 2022 | 8 | 10 |
| 2023 | 2 | 11 |
| 2024 | 13 | 14 |
| 2025 | 3 | 16 |
| 2026 | 4 | 7 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- AAV-IDS vectors for treatment of mucopolysaccharidosis II7 Jul 2026US 12,673,117 B2The University of North Carolina at Chapel Hill
- Formulations of protein molecules comprising iduronate 2-sulfatase30 Jun 2026US 12,667,606 B2Denali Therapeutics Inc.
- Application of microbial glycosidase as an anti-viral therapeutic, prognostic, and diagnostic26 May 2026US 12,636,353 B2The Regents of the University of California
- Anti-transferrin receptor fusion proteins and methods of use thereof26 May 2026US 12,636,363 B2Denali Therapeutics Inc.
- CNS delivery of therapeutic agents9 Sep 2025US 12,409,210 B2Takeda Pharmaceutical Company Limited
- Gene therapy for treating mucopolysaccharidosis type ii1 Oct 2026US 2026/0295085 A1The Trustees of the University of Pennsylvania
- Peptide Having Affinity for Human Transferrin Receptor24 Sep 2026US 2026/0285942 A1JCR Pharmaceuticals Co., Ltd.
- Method for improving neurological function in mpsi and mpsii and other neurological disorders20 Aug 2026US 2026/0241038 A1Regents of the University of Minnesota
- Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier2 Jul 2026US 2026/0184781 A1JCR Pharmaceuticals Co., Ltd.
- Gene therapy constructs for metabolic disorders4 Jun 2026US 2026/0152730 A1Erasmus University Medical Center Rotterdam
Most cited
By later US patents
- Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases78US 9,249,424 B2HealthPartners Research & Education · 2016
- Assay for measuring enzymatic modification of a substrate by a glycoprotein having enzymatic activity29US 9,140,635 B2Advanced Liquid Logic, Inc. · 2015
- Methods and compositions for CNS delivery of iduronate-2-sulfatase27US 8,545,837 B2Shire Human Genetic Therapies, Inc. · 2013
- Cell that expresses a sulfatase and a formylglycine generating enzyme22US 8,227,212 B2Shire Human Genetic Therapies, Inc. · 2012
- CNS delivery of therapeutic agents21US 9,283,181 B2Shire Human Genetic Therapies, Inc. · 2016